BioVie, Inc. (BIVI)
Stock Price:
$9.06 USD
-0.12 (-1.31%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
63.48M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-16.68M |
| Shares Out |
7.01M |
| EPS (ttm) |
-6.85 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$9.06 |
| Previous Close |
$9.18 |
| Change ($) |
-0.12 |
| Change (%) |
-1.31% |
| Day's Open |
9.22 |
| Day's Range |
9.00 - 9.25 |
| Day's Volume |
9,099 |
| 52-Week Range |
2.20 - 34.54 |
More Stats
| Market Cap |
63.48M |
| Enterprise Value |
64.35M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
7.01M |
| Float |
1.25M |
| EPS (basic) |
-6.85 |
| EPS (diluted) |
-6.85 |
| FCF / Share |
-0.33 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4,917 |
| Short Ratio |
0.11 |
| Short % of Float |
0.39% |
| Beta |
2.66 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
13.99 |
| Revenue |
n/a |
| Operating Income |
-2.69M |
| Net Income |
-16.68M |
| Free Cash Flow |
-1.63M |
| Net Cash |
-873,848 |
| Net Cash / Share |
-0.12 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-72.26% |
| ROE |
826.55% |
| ROIC |
117.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | - | - | - | - | - | - | - |
| Operating Income | -2.69 | -2.50 | -2.37 | -1.55 | -0.43 | -0.23 | -0.32 |
| Net Income | -16.68 | -2.44 | -2.41 | -1.33 | -0.43 | -0.23 | -0.32 |
| Shares Outstanding | 4.93 | 2.54 | 0.77 | 0.72 | 0.70 | 0.70 | 0.70 |
| Earnings Per Share | -6.85 | -0.98 | -3.75 | -1.25 | - | - | - |
| Operating Cash Flow | -1.63 | -2.50 | -0.62 | -0.62 | -0.15 | -0.07 | -0.17 |
| Free Cash Flow | -1.63 | -2.50 | -0.62 | -0.62 | -0.15 | -0.07 | -0.17 |
| Cash & Equivalents | 0.04 | 0.34 | 0.05 | 0.01 | 0.12 | 0.27 | 0.33 |
| Total Debt | 0.91 | - | 0.83 | 0.61 | 0.01 | - | - |
| Net Cash / Debt | -0.87 | 0.34 | -0.78 | -0.61 | 0.11 | 0.27 | 0.33 |
| Assets | 2.08 | 2.57 | 2.18 | 2.36 | 2.72 | 0.27 | 0.33 |
| Liabilities | 23.58 | 0.44 | 2.06 | 1.21 | 0.80 | 0.32 | 0.16 |
| Book Value | -21.50 | 2.13 | 0.11 | 1.16 | 1.92 | -0.05 | 0.17 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
BioVie, Inc. |
| Country |
United States |
| Employees |
2 |
| CEO |
Terren S. Peizer |
Stock Information
| Ticker Symbol |
BIVI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: BIVI |
Description
BioVie, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.